Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Seeking Buyer or Merger Partner; Interim CEO Steps Down

NEW YORK (GenomeWeb News) – Oncology screening company Exact Sciences said it is seeking “strategic alternatives for the business,” which could include merging with or being bought by another company.
Marlborough, Mass.-based Exact, which has a license and marketing agreement with Laboratory Corporation of American for the sale of a colorectal cancer screening test, said today it has retained investment banking firm Leerink Swan to help it evaluate opportunities.
The company said earlier this month that its stool-based DNA screening technology was included in the American Cancer Society’s updated guidelines for colorectal cancer screening.
In a filing with the US Securities and Exchange Commission today, Exact said that interim CEO Patrick Zenner has stepped down from that post, and the firm has named President Jeffrey Luber to the CEO spot “until his successor is duly elected and qualified or until his earlier resignation or removal.” Luber also has been given a seat on the company’s board of directors.
Zenner retained his position as executive chairman of the board of directors of Exact.
Exact Sciences’ shares were trading up 9.2 percent at $2.86 on the Nasdaq in early Tuesday trade. In late February, the company’s stock had hit a 52-week low of $1.70 a share.
In October, Exact Sciences received a warning letter from the US Food and Drug Administration’s Office of In Vitro Diagnostics Device Evaluation and Safety regarding its PreGen-Plus colorectal screening technology. The agency said that the test is a medical device that requires premarket approval.
LabCorp has rights to exclusively distribute the PreGen-Plus test through 2010.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.